Patient stratification by genetic risk in Alzheimer’s disease is only effective in the presence of phenotypic heterogeneity
PLOS ONE · 2025
DOI: 10.1371/journal.pone.0310977 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2025. Verfasst von Jack Euesden und 7 weiteren Autor:innen. Beteiligte Einrichtung: Biostatistics, GSK Pharma R&D, Stevenage, Hertfordshire, United Kingdom. Hauptthemen laut MEDLINE: Alzheimer Disease, Genome-Wide Association Study, Genetic Predisposition to Disease, Mendelian Randomization Analysis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, Foundation for the National Institutes of Health, Chan Zuckerberg Initiative.
Themen: Demenz
Abstract (Originalsprache)
Case-only designs in longitudinal cohorts are a valuable resource for identifying disease-relevant genes, pathways, and novel targets influencing disease progression. This is particularly relevant in Alzheimer’s disease (AD), where longitudinal cohorts measure disease “progression,” defined by rate of cognitive decline. Few of the identified drug targets for AD have been clinically tractable, and phenotypic heterogeneity is an obstacle to both clinical research and basic science. In four cohorts (n = 7241), we performed genome-wide association studies (GWAS) and Mendelian randomization (MR) to discover novel targets associated with progression and assess causal relationships. We tested opportunities for patient stratification by deriving polygenic risk scores (PRS) for AD risk and severity and tested the value of these scores in predicting progression. Genome-wide association studies identified no loci associated with progression at genome-wide significance (α = 5×10 −8 ); MR analyses provided no significant evidence of an association between cognitive decline in AD patients and protein levels in brain, cerebrospinal fluid (CSF), and plasma. Polygenic risk scores for AD risk did not reliably stratify fast from slow progressors; however, a deeper investigation found that APOE ε4 status predicts amyloid-β and tau positive versus negative patients (odds ratio for an additional APOE ε4 allele = 5.78 [95% confidence interval: 3.76–8.89], P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Biostatistics, GSK Pharma R&D, Stevenage, Hertfordshire, United Kingdom.
- Washington University School of Medicine, NeuroGenomics and Informatics Center, St. Louis, MO, United States of America.
- Genomic Sciences, GSK Pharma R&D, Collegeville, PA, United States of America.
- Genomic Sciences, GSK Pharma R&D, Stevenage, Hertfordshire, United Kingdom.
- Genomic Sciences, GSK Pharma R&D, Cambridge, MA, United States of America.
ORCID-Profile: Jack Euesden, David Pulford
Förderung
- NIA NIH HHS
- Foundation for the National Institutes of Health
- Chan Zuckerberg Initiative
Zitieren
APA
Euesden, J., Ali, M., Robins, C., Surendran, P., Gormley, P., Alzheimer’s Disease Neuroimaging Initiative (ADNI), Pulford, D., & Cruchaga, C. (2025). Patient stratification by genetic risk in Alzheimer’s disease is only effective in the presence of phenotypic heterogeneity. PLOS ONE. https://doi.org/10.1371/journal.pone.0310977
Vancouver
Euesden J, Ali M, Robins C, Surendran P, Gormley P, Alzheimer’s Disease Neuroimaging Initiative (ADNI), et al. Patient stratification by genetic risk in Alzheimer’s disease is only effective in the presence of phenotypic heterogeneity. PLOS ONE. 2025. doi:10.1371/journal.pone.0310977
BibTeX
@article{Euesden2025,
author = {Euesden, Jack and Ali, Muhammad and Robins, Chloe and Surendran, Praveen and Gormley, Padhraig and Alzheimer’s Disease Neuroimaging Initiative (ADNI), Alzheimer’s Disease Neuroimaging Initiative (ADNI) and Pulford, David and Cruchaga, Carlos},
title = {Patient stratification by genetic risk in Alzheimer’s disease is only effective in the presence of phenotypic heterogeneity},
journal = {PLOS ONE},
year = {2025},
doi = {10.1371/journal.pone.0310977}
}
EUVIMED